Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. AWK
5. SPCX
6. III
7. TTEC
8. DAL
9. IOVA
10. CHDN

Go back to Eli Lilly & Co. (LLY) & Incyte (INCY) Report Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib
Incyte Genomics, Inc. (NASDAQ: INCY) Delayed: 98.22 -0.77 (0.78%)
Previous Close $98.99    52 Week High $118.49 
Open $99.58    52 Week Low $55.00 
Day High $99.62    P/E N/A 
Day Low $96.09    EPS $-0.56 
Volume 4,058,624       

Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1098.57 -13.43 (1.21%)
Previous Close $1112.00    52 Week High $88.16 
Open $1120.49    52 Week Low $67.88 
Day High $1122.33    P/E 254.30 
Day Low $1088.66    EPS $4.32 
Volume 4,470,563